详情页 - 昆明医科大学第一附属医院知识库

资源类型：

文章类型：

作者：

Chi, Yihebali[1,2,3,4,5,6,7,8,9,10,11,12,13,14] ; Gao, Ming[1,2,3,4,5,6,7,8,9,10,11,12,13,14] ; Tang, Pingzhang[1,2,3,4,5,6,7,8,9,10,11,12,13,14] ; Zheng, Xiangqian[1,2,3,4,5,6,7,8,9,10,11,12,13,14] ; Xu, Zhengang[1,2,3,4,5,6,7,8,9,10,11,12,13,14] ; Li, Dapeng[1,2,3,4,5,6,7,8,9,10,11,12,13,14] ; Chen, Xiaohong[1,2,3,4,5,6,7,8,9,10,11,12,13,14] ; Ge, Minghua[1,2,3,4,5,6,7,8,9,10,11,12,13,14] ; Zhang, Yuan[1,2,3,4,5,6,7,8,9,10,11,12,13,14]

; Guo, Zhuming[1,2,3,4,5,6,7,8,9,10,11,12,13,14] ; Wang, Jun[1,2,3,4,5,6,7,8,9,10,11,12,13,14]

; Chen, Jie[1,2,3,4,5,6,7,8,9,10,11,12,13,14]

; Zhang, Jiewu[1,2,3,4,5,6,7,8,9,10,11,12,13,14] ; Cheng, Ying[1,2,3,4,5,6,7,8,9,10,11,12,13,14]

; Li, Zhendong[1,2,3,4,5,6,7,8,9,10,11,12,13,14] ; Liu, Hui[1,2,3,4,5,6,7,8,9,10,11,12,13,14] ; Qin, Jianwu[1,2,3,4,5,6,7,8,9,10,11,12,13,14] ; Zhu, Jingqiang[1,2,3,4,5,6,7,8,9,10,11,12,13,14] ; Cheng, Ruochuan[1,2,3,4,5,6,7,8,9,10,11,12,13,14]

;

机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China [2]Tianjin Med Univ, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Lab Canc Prevent & The, Key Lab Canc Prevent & Therapy,Canc Inst & Hosp, Tianjin, Peoples R China [3]Capital Med Univ, Beijing Tongren Hosp, Beijing, Peoples R China [4]Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp,Hangzhou Med Coll, Chinese Acad Sci,Inst Canc & Basic Med ICBM,Peopl, Hangzhou, Peoples R China [5]Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Jiangsu Canc Hosp, Nanjing, Peoples R China [6]Sun Yat Sen Univ Canc Ctr, Guangzhou, Peoples R China [7]Gansu Prov Canc Hosp, Lanzhou, Peoples R China [8]Hunan Canc Hosp, Changsha, Peoples R China [9]China Med Univ, Liaoning Tumor Hosp & Inst, Tumor Hosp, Shenyang, Peoples R China [10]Fujian Canc Hosp, Fuzhou, Peoples R China [11]Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China [12]Henan Canc Hosp, Zhengzhou, Peoples R China [13]Sichuan Univ, West China Hosp, Chengdu, Peoples R China [14]Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China

出处：

DOI：

ISSN：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2020]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China [2]Tianjin Med Univ, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Lab Canc Prevent & The, Key Lab Canc Prevent & Therapy,Canc Inst & Hosp, Tianjin, Peoples R China [3]Capital Med Univ, Beijing Tongren Hosp, Beijing, Peoples R China [4]Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp,Hangzhou Med Coll, Chinese Acad Sci,Inst Canc & Basic Med ICBM,Peopl, Hangzhou, Peoples R China [5]Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Jiangsu Canc Hosp, Nanjing, Peoples R China [6]Sun Yat Sen Univ Canc Ctr, Guangzhou, Peoples R China [7]Gansu Prov Canc Hosp, Lanzhou, Peoples R China [8]Hunan Canc Hosp, Changsha, Peoples R China [9]China Med Univ, Liaoning Tumor Hosp & Inst, Tumor Hosp, Shenyang, Peoples R China [10]Fujian Canc Hosp, Fuzhou, Peoples R China [11]Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China [12]Henan Canc Hosp, Zhengzhou, Peoples R China [13]Sichuan Univ, West China Hosp, Chengdu, Peoples R China [14]Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Exploration of associations between adverse drug reactions and clinical outcomes in anlotinib treatment against medullary thyroid carcinoma (MTC): A subgroup analysis based on the ALTER01031 trial.

文献详情